July 26, 2019 - 9:00am

Health and Human Services Commission, Brown-Heatly Building, Public Hearing Room 1400
4900 North Lamar Blvd.
Austin Texas, 78751

Agenda

Webcasting Available

This meeting will be webcast. To access the webcast, go to https://hhs.texas.gov/about-hhs/communications-events/live-archived-meetings the day and time of the meeting.

1. Call to order
2. Approval of minutes from April 26, 2019 (vote required)
3. Re-drawing of member terms to establish term length: Stephanie Gutierrez – Advisory Committee Coordination Office
4. New business:

   Public comment on drug classes to be reviewed for the Medicaid Preferred Drug List (PDL):

   1. Alzheimer’s agents
   2. Antihistamines, minimally sedating
   3. Antihypertensives, sympatholytics
   4. Calcium channel blockers
   5. Cephalosporins and related antibiotics
   6. Fluoroquinolones, oral
   7. Glucocorticoids, oral
   8. Immunosuppressives, oral
   9. Iron, oral
   10. Leukotriene modifiers
   11. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
   12. Ophthalmic antibiotics
   13. Ophthalmic antibiotic-steroid combinations
   14. Ophthalmic for allergic conjunctivitis
   15. Ophthalmic, anti-inflammatories
   16. Ophthalmic, anti-inflammatories/immunomodulator
   17. Ophthalmic, glaucoma agents
   18. Otic antibiotics
   19. Otic anti-infectives and anesthetics
   20. Progestational agents
   21. Sickle cell anemia treatments
   22. Skeletal muscle relaxants
   23. Steroids, topical high
   24. Steroids, topical low
   25. Steroids, topical medium
   26. Steroids, topical very high
   27. Ulcerative colitis agents
5. Public comment and therapeutic and clinical drug reviews on new drugs to be reviewed for the Medicaid PDL:
   1. Apadaz / Analgesics, Narcotics Short
   2. Inbrija / Antiparkinsons Agents
   3. Nivestym vial / Colony Stimulating Factors
   4. Tremfya Autoinjector, Skyrizi / Cytokine and Cell Adhesion Molecule (CAM) Antagonists
   5. Motegrity / Gastrointestinal (GI) Motility, Chronic
   6. Ingrezza Initiation Pack / Movement Disorders
6. Therapeutic and Clinical Drug Reviews and Updates: Matt Lennertz, Pharm. D., Magellan Medicaid Administration
7. Executive work session

   Pursuant to Texas Government Code Section 531.071, and in accordance with Texas Administrative Code Title 1, Part 15, Subchapter F, Section 354.1941(c)(2), the Drug Utilization Review (DUR) Board may meet in executive session on one or more items listed under new business as permitted by the Texas Open Meetings Act.

8. Announcements of drugs recommended for the Medicaid PDL: Matt Lennertz, Pharm. D., Magellan Medicaid Administration (vote required)
9. Retrospective DUR: Larry Dent, Pharm. D., BCPS, Conduent, LLC
   1. Report on recent retrospective DUR interventions:
      1. Medication Adherence
      2. Mental Health Disorders
      3. Psychotropic Drug in Adults
   2. Report on recent retrospective DUR intervention outcomes:
      1. Benzodiazepine Anxiolytics and Controlled Sedative Hypnotics
      2. Major Depressive Disorder Management
   3. Retrospective DUR proposals (vote required)
      1. Attention Deficit Hyperactivity Disorder (ADHD) Medication Management
      2. Cough and Cold Medications
      3. Influenza Prevention
10. Prospective prior authorization proposals (clinical edits): Christina Faulkner, Pharm. D., Health Information Designs, LLC (vote required)
    1. Cytokine and CAM antagonists - addition of Skyrizi (risankizumab-rzaa)
    2. GI Motility – Addition of Motegrity (prucalopride)
    3. Skeletal Muscle Relaxants - Update
11. Retrospective drug use, criteria for outpatient use in Vendor Drug Program: Jennifer Seltzer, Pharm. D., University of Texas at Austin College of Pharmacy (vote required)
    1. Acetylcholinesterase Inhibitors
    2. Cyclooxygenase (COX)-2 Inhibitors
    3. Hepatitis C Direct Acting Antivirals
    4. Histamine H2-Receptor Antagonists
    5. Ketorolac
    6. Leukotriene Receptor Antagonists
    7. Mecasermin
    8. Memantine
12. Next meeting date: October 25, 2019
13. Adjourn

Contact: Questions regarding agenda items, content, or meeting arrangements should be directed to Alish Valdez, DUR/Formulary Support Specialist, Health and Human Services Commission, Medicaid and CHIP Services Department, at 512-707-6136 or VDP-Advisory@hhsc.state.tx.us.

Information regarding submission of written comments and application to provide public testimony before the committee can be found at: https://www.txvendordrug.com/resources/drug-utilization-review-board/dur-board-meetings.

This meeting is open to the public. No reservations are required, and there is no cost to attend this meeting.

People with disabilities who wish to attend the meeting and require auxiliary aids or services should contact Valdez at 512-707-6136 or VDP-Advisory@hhsc.state.tx.us at least 72 hours before the meeting so appropriate arrangements can be made.